Tycko & Zavareei LLP is currently investigating coverage denials by insurance companies of life-saving Hepatitis C treatments. Hepatitis C is a chronic infection that afflicts millions of people around the world and, by some estimates, results in 15,000 deaths per year in the United States. It has been estimated that up to 70 percent of people with Hepatitis C will develop chronic liver disease, up to 20 percent will eventually develop cirrhosis, a severe scarring of the liver, and up to 5 percent will develop liver cancer.
The U.S. Food and Drug Administration recently approved Harvoni, a new drug manufactured by Gilead Sciences Inc., with a high cure rate of Hepatitis C and with fewer side effects than other treatments. Its predecessor was Sovaldi, also manufactured by Gilead. Yet despite the recent availability of this promising curative treatment for Hepatitis C, many insurance companies are denying coverage for the drug due to its high cost.
If you or someone you know has been denied insurance coverage for Hepatitis C treatment, please fill out the contact form below and someone from our firm will contact you about your experience. You may also call our firm directly at (202) 973-0900.